Mankind Pharma Limited has informed the Exchange about Acquisition

Strategic Transactions View source PDF Explain this filing

MANKIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.5%Reaction day

₹2470.00

prior close

₹2501.00

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.4%+4.1% vs market

Pharmaceuticals peers, median of 158sector+0.2%+4.2% vs sector

On the reaction day the stock moved 4.1 pts more than Nifty Midcap 150 and 4.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.2

10m

+2.1

15m

+2.2

30m

+2.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.5+0.4+4.1+0.2+4.2

Next day

+2.0+0.5+1.5+0.7+1.3

+0.4+0.6-0.1+0.5-0.1

-0.4+1.4-1.9+1.8-2.2

-2.2+1.9-4.1+1.9-4.2

-1.5+2.3-3.7+2.0-3.5

-6.2-0.5-5.7+1.3-7.5

15d

-3.8-2.9-1.0-0.5-3.3

+3.0+3.1-0.2+4.1-1.1

+4.3+3.2+1.1+8.4-4.1

-3.4+4.5-8.0+9.1-12.6

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 158Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Mankind Pharma reported audited standalone revenue of ₹10,421 Crores for FY2026, up 9.6% from ₹9,507 Crores in FY2025. Profit after tax stood at ₹713.61 Crores with basic EPS of ₹17.29. The Board approved additional investment of up to ₹500 Crores in its wholly-owned subsidiary Mankind Medicare Private Limited. Executive Directors (Chairman, Vice Chairman & MD, and CEO) voluntarily waived their commission for FY2025-26 to strengthen the company's cash position for business expansion. The Board also reappointed Mr. Satish Kumar Sharma as Whole-Time Director for 5 years and approved Cost Auditor reappointment.

Likely market impact

Strong financial performance with 9.6% revenue growth and profit expansion indicates healthy operational performance. The ₹500 Crore investment in subsidiary signals continued expansion plans while executive commission waiver reflects management confidence in future growth.